References
- 1.ZHENG R S,ZHANG S W,ZENG H M,et al.Cancer incidence and mortality in China,2016[J].J Natl Cancer Cent,2022,2(1):1-9.
- 2.CHEN J,SONG Y,LI Y,et al.A trans-omics assessment of gene-gene interaction in early-stage NSCLC[J].Mol Oncol,2023,17(1):173-187.
- 3.WANG Z H,EMBAYE K S,YANG Q,et al.Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism-related genes[J].Cancer Cell Int,2021,21(1):219.
- 4.GONG W J,ZHOU T,ZENG H A,et al.Study on the correlation between Let-7a-2 rs629367 and pri-miR-218 rs11134527 and the toxic side effects of platinum based combination chemotherapy in lung cancer[J].Chin J Hosp Pharm,2024,44(5):576-584.
- 5.ZHOU C C,WANG Y N,ZHAO J,et al.Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy[J].Clin Cancer Res,2021,27(5):1296-1304.
- 6.SUN H P,XU L F,LIU X,et al.Molecular mechanism research of Astragalus membranaceus and Hedyotis diffusa regulate LINC01134-CTCF-p21 axis to inhibit lung adenocarcinoma proliferation[J].Chin J Exp Tradit Med Form,2025,31(4):116-124.
- 7.UXA S,BERNHART S H,MAGES C F S,et al.DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation[J].Nucleic Acids Res,2019,47(17):9087-9103.
- 8.STURMLECHNER I,ZHANG C,SINE C C,et al.p21 produces a bioactive secretome that places stressed cells under immunosurveillance[J].Science,2021,374(6567):eabb3420.
- 9.WANG Y Q,WU Y Q,ZHENG P.The effect of lncRNA HOTAIR targeted regulation of vasodilator activated phosphoprotein on the migration and invasion of cervical cancer cells [J]. Chin J Cancer Prev Trea,2023,30(12):708-717.
- 10.TANG J X,ZHANG J H,LU Y,et al.Novel insights into the multifaceted roles of m6A-modified LncRNAs in cancers:Biological functions and therapeutic applications[J].Biomark Res,2023,11(1):42.
- 11.WANG C,CHEN Y,CHEN K L,et al.Long noncoding RNA LINC01134 promotes hepatocellular carcinoma metastasis via activating AKT1S1 and NF-κB signaling[J].Front Cell Dev Biol,2020,8:429.
- 12.CALCINOTTO A,KOHLI J,ZAGATO E,et al.Cellular senescence:Aging,cancer,and injury[J].Physiol Rev,2019,99(2):1047-1078.
- 13.MA L N,BAJIC V B,ZHANG Z.On the classification of long non-coding RNAs[J].RNA Biol,2013,10(6):924-933.
- 14.YAO R W,WANG Y,CHEN L L.Cellular functions of long noncoding RNAs[J].Nat Cell Biol,2019,21(5):542-551.
- 15.LI K,WANG Z Q.lncRNA NEAT1:Key player in neurodegenerative diseases[J].Ageing Res Rev,2023,86:101878.
- 16.CUSENZA V Y,TAMENI A,NERI A,et al.The lncRNA epigenetics:The significance of m6A and m5C lncRNA modifications in cancer[J].Front Oncol,2023,13:1063636.
- 17.YU Y T,WANG J L,GUO Q F,et al.LINC01134:A pivotal oncogene with promising predictive maker and therapeutic target in hepatocellular carcinoma[J].Front Oncol,2024,14:1265762.
- 18.DENG X Y,XIONG W,JIANG X J,et al.LncRNA LINC00472 regulates cell stiffness and inhibits the migration and invasion of lung adenocarcinoma by binding to YBX1[J].Cell Death Dis,2020,11(11):945.
- 19.RONG Z H,WANG Z Y,WANG X X,et al.Molecular interplay between linc01134 and YY1 dictates hepatocellular carcinoma progression[J].J Exp Clin Cancer Res,2020,39(1):61.
- 20.WANG J,HE Z W,LIU X Y,et al.LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2[J].Cell Death Dis,2022,13(8):718.
- 21.MA L Y,XU A,KANG L,et al.LSD1-demethylated LINC01134 confers oxaliplatin resistance through SP1-induced p62 transcription in HCC[J].Hepatology,2021,74(6):3213-3234.
- 22.PENG B,LI R T,YAN Q D,et al.Pharmacological mechanism and research progress of Hedyotis diffusa in the treatment of non-small cell lung cancer[J].J Liaoning Univ Tradit Chin Med,2024,26(10):174-179.
- 23.HUANG L,CHEN B L,LUO L.Research progress on chemical components,pharmacological effects,and clinical applications of Hedyotis diffusa[J].Chin Pharm Aff,2023,37(12):1451-1460.
- 24.LIU S Y.Clinical and mechanistic study on the inhibition of lung adenocarcinoma by lung antitumor agents based on the IL-6/PI3K/Akt/mTOR pathway[D].Jinan:Shandong University of Traditional Chinese Medicine,2019.


